C1 inhibitor: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: C1INH ==Adult Dosing== ===Angioedema<ref>Craig TJ, Levy RJ, Wasserman RL, et al. Eff...") |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: human C1 inhibitor (plasma product) | ||
*Dosage Forms: | *Dosage Forms: 20 iU/kg | ||
*Routes of Administration: | *Routes of Administration: IV/SQ | ||
*Common Trade Names: | *Common Trade Names: Cinryze, Berinert | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Angioedema<ref>Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801.</ref>=== | ===[[Angioedema]]<ref>Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801.</ref>=== | ||
*1000 units if ≤50kg | *1000 units if ≤50kg | ||
*1500 units if >50-75kg | *1500 units if >50-75kg | ||
Latest revision as of 14:30, 16 August 2020
Administration
- Type: human C1 inhibitor (plasma product)
- Dosage Forms: 20 iU/kg
- Routes of Administration: IV/SQ
- Common Trade Names: Cinryze, Berinert
Adult Dosing
Angioedema[1]
- 1000 units if ≤50kg
- 1500 units if >50-75kg
- 2000 units if >75-100kg
- 2500 units if >100kg
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801.